{"id":"mitoguazone","rwe":[{"pmid":"37300541","year":"2023","title":"Barley HOMOCYSTEINE METHYLTRANSFERASE 2 confers drought tolerance by improving polyamine metabolism.","finding":"","journal":"Plant physiology","studyType":"Clinical Study"},{"pmid":"38619931","year":"2020","title":"Rapid Structure-Based Screening Informs Potential Agents for Coronavirus Disease (COVID-19) Outbreak.","finding":"","journal":"Chinese physics letters","studyType":"Clinical Study"},{"pmid":"17116678","year":"2007","title":"Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs.","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"},{"pmid":"15549180","year":"2004","title":"Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis.","finding":"","journal":"Cellular and molecular life sciences : CMLS","studyType":"Clinical Study"},{"pmid":"15541750","year":"2004","title":"Effect of mitoguazone on polyamine oxidase activity in rat liver.","finding":"","journal":"Toxicology and applied pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"mitoguazone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01XX16","category":"atc"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"methylglyoxal bis(guanylhydrazone)","offLabel":[],"synonyms":["mitoguazone","Methylglyoxal bis(amidinohydrazone)","Methylglyoxal bis(guanylhydrazone)"],"timeline":[],"aiSummary":"Methylglyoxal Bis(Guanylhydrazone), also known as mitoguazone, is a small molecule drug in the mitoguazone class. Its exact target is unknown, but it is used to treat certain types of cancer. The commercial status of mitoguazone is unclear, and it may be patented or available as a generic medication. Key safety considerations include potential side effects and interactions with other medications. Further research is needed to fully understand the pharmacology and clinical use of mitoguazone.","approvals":[],"brandName":"Methylglyoxal Bis(Guanylhydrazone)","ecosystem":[],"mechanism":{"target":"Amiloride-sensitive amine oxidase [copper-containing], S-adenosylmethionine decarboxylase proenzyme","modality":"Small Molecule","drugClass":"mitoguazone","explanation":"Think of mitoguazone like a brake on a car. The brake (mitoguazone) slows down the car (DNA synthesis and repair) by blocking the accelerator (ribonucleotide reductase). This can help prevent cancer cells from growing and dividing.","oneSentence":"Mitoguazone works by inhibiting the enzyme ribonucleotide reductase, which is involved in DNA synthesis and repair.","technicalDetail":"Mitoguazone specifically binds to the B2 subunit of ribonucleotide reductase, inhibiting its activity and thereby reducing DNA synthesis and repair in rapidly dividing cells such as cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3362","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MITOGUAZONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MITOGUAZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:48:52.406422","biosimilars":[],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"altretamine","drugSlug":"altretamine","fdaApproval":"1990-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"denileukin diftitox","drugSlug":"denileukin-diftitox","fdaApproval":"1999-02-05","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eribulin","drugSlug":"eribulin","fdaApproval":"2010-11-15","patentExpiry":"Jul 8, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"mitoguazone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"altretamine","brandName":"altretamine","genericName":"altretamine","approvalYear":"1990","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"denileukin-diftitox","brandName":"denileukin diftitox","genericName":"denileukin diftitox","approvalYear":"1999","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07468136","phase":"PHASE1,PHASE2","title":"Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-04-24","conditions":["Anaplastic Oligodendroglioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Diffuse Astrocytoma","Glioblastoma, IDH-Wildtype","Malignant Glioma"],"enrollment":33,"completionDate":"2030-10-25"},{"nctId":"NCT06056895","phase":"PHASE2","title":"Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2023-11-08","conditions":["Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Merkel Cell Carcinoma AJCC v8","Merkel Cell Carcinoma"],"enrollment":12,"completionDate":"2027-04-30"},{"nctId":"NCT06320405","phase":"PHASE1,PHASE2","title":"Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-05-21","conditions":["Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm"],"enrollment":38,"completionDate":"2029-04-01"},{"nctId":"NCT05455697","phase":"PHASE1,PHASE2","title":"Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-01-26","conditions":["Diffuse Large B-Cell Lymphoma","Grade 3b Follicular Lymphoma","High Grade B-Cell Lymphoma"],"enrollment":35,"completionDate":"2027-07-06"},{"nctId":"NCT04445844","phase":"PHASE2","title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mridula George, MD","startDate":"2020-07-13","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8","Triple-negative Breast Cancer"],"enrollment":25,"completionDate":"2025-06-30"},{"nctId":"NCT06160206","phase":"PHASE2","title":"Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2024-10-02","conditions":["Recurrent Glioblastoma","Recurrent WHO Grade 4 Glioma"],"enrollment":134,"completionDate":"2030-11-30"},{"nctId":"NCT03040154","phase":"NA","title":"Engaging Immigrants in Preventive Parenting Interventions","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2016-06","conditions":["Health Behavior","Parenting","Social Acceptance"],"enrollment":217,"completionDate":"2016-12"},{"nctId":"NCT04158726","phase":"NA","title":"Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Carevive Systems, Inc.","startDate":"2019-04-26","conditions":["Acute Myeloid Leukemia"],"enrollment":47,"completionDate":"2020-12-31"},{"nctId":"NCT04776876","phase":"PHASE2","title":"Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-01","conditions":["Advanced Neuroendocrine Neoplasm","Carcinoid Syndrome"],"enrollment":0,"completionDate":"2021-09-02"},{"nctId":"NCT00963911","phase":"NA","title":"Validation of a Screening Tool in Geriatric Oncology","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-08-05","conditions":["Breast Cancer","Colorectal Cancer","Head and Neck Cancer","Lung Cancer","Lymphoma","Prostate Cancer"],"enrollment":1674,"completionDate":"2015-03-08"},{"nctId":"NCT00002348","phase":"PHASE2","title":"A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"","conditions":["Lymphoma, Non-Hodgkin","HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT03595956","phase":"","title":"Transgender Cohort Study of Gender Affirmation and HIV-related Health","status":"UNKNOWN","sponsor":"Fenway Community Health","startDate":"2019-02-11","conditions":["HIV/AIDS","STI","Gender Dysphoria","Transsexualism","Gender Identity","Depression, Anxiety"],"enrollment":4500,"completionDate":"2021-12"},{"nctId":"NCT03267927","phase":"NA","title":"Management of Obstructive Sleep Apnea (OSA) in Children and Maxillary and Mandibular Development","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2017-11-05","conditions":["Obstructive Sleep Apnea Syndrome"],"enrollment":4,"completionDate":"2019-03-25"},{"nctId":"NCT02364050","phase":"","title":"Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-09","conditions":["Lymphoma, Large B-Cell, Diffuse"],"enrollment":1300,"completionDate":"2020-12"},{"nctId":"NCT02242604","phase":"","title":"Characterization of Neuropsychologic and Physical Performance in Geriatric Patients With Hyponatremia.","status":"COMPLETED","sponsor":"Volker Burst","startDate":"2014-04","conditions":["Hyponatremia"],"enrollment":100,"completionDate":"2017-08"},{"nctId":"NCT03662191","phase":"PHASE1","title":"Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-28","conditions":["Healthy Volunteers"],"enrollment":9,"completionDate":"2019-01-10"},{"nctId":"NCT03266705","phase":"PHASE1","title":"A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-20","conditions":["Healthy"],"enrollment":30,"completionDate":"2018-03-01"},{"nctId":"NCT03280173","phase":"PHASE1","title":"A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-29","conditions":["Healthy"],"enrollment":18,"completionDate":"2018-02-23"},{"nctId":"NCT02746926","phase":"PHASE1","title":"A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04-29","conditions":["Healthy"],"enrollment":12,"completionDate":"2016-07-15"},{"nctId":"NCT02697864","phase":"PHASE1","title":"A Study Comparing Amounts of Tafamidis In The Blood Without Food","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04","conditions":["Healthy"],"enrollment":12,"completionDate":"2016-06"},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":["Lymphoma"],"enrollment":442,"completionDate":"2016-03"},{"nctId":"NCT00956332","phase":"PHASE1,PHASE2","title":"Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"MultiGene Vascular Systems Ltd.","startDate":"2010-02","conditions":["Peripheral Arterial Disease","Peripheral Vascular Disease","Critical Limb Ischemia"],"enrollment":28,"completionDate":"2026-05"},{"nctId":"NCT00390767","phase":"PHASE1,PHASE2","title":"Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)","status":"UNKNOWN","sponsor":"MultiGene Vascular Systems Ltd.","startDate":"2006-10","conditions":["PAD","Claudication"],"enrollment":12,"completionDate":"2024-12"},{"nctId":"NCT02106403","phase":"NA","title":"A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05","conditions":["Skin Care"],"enrollment":50,"completionDate":"2014-06"},{"nctId":"NCT02189330","phase":"PHASE1","title":"A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-05","conditions":["Healthy Volunteers"],"enrollment":24,"completionDate":"2014-07"},{"nctId":"NCT00925873","phase":"PHASE3","title":"GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1996-06","conditions":["Acute Myeloid Leukemia"],"enrollment":303,"completionDate":"2004-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"006109","UNII":"OD5Q0L447W","CHEBI":"CHEBI:43996","INN_ID":"2453","UMLSCUI":"C0026251","ChEMBL_ID":"CHEMBL216913","KEGG_DRUG":"D07258","DRUGBANK_ID":"DB12967","PDB_CHEM_ID":" MGB","PUBCHEM_CID":"5351154","MESH_DESCRIPTOR_UI":"D008935"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":65,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XX16","allCodes":["L01XX16"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Aug 31","pmid":"37300541","title":"Barley HOMOCYSTEINE METHYLTRANSFERASE 2 confers drought tolerance by improving polyamine metabolism.","journal":"Plant physiology"},{"date":"2020 May","pmid":"38619931","title":"Rapid Structure-Based Screening Informs Potential Agents for Coronavirus Disease (COVID-19) Outbreak.","journal":"Chinese physics letters"},{"date":"2007 Feb","pmid":"17116678","title":"Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2004 Nov","pmid":"15549180","title":"Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis.","journal":"Cellular and molecular life sciences : CMLS"},{"date":"2004 Dec 1","pmid":"15541750","title":"Effect of mitoguazone on polyamine oxidase activity in rat liver.","journal":"Toxicology and applied pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}